Here is the SEO-optimized, complete English translation of the provided text. All terms, medical titles, dates, and publication records have been accurately translated and formatted for search engine visibility.

About Prof. Dr. Semir Pasa | Specialist in Internal Medicine

Born in Antakya in 1977, Prof. Dr. Semir Pasa is a distinguished medical professor with extensive clinical and academic expertise in Internal Medicine (Dahiliye). Adopting an evidence-based, scientific approach to diagnosis, treatment, and follow-up care, Prof. Dr. Pasa provides comprehensive medical services for adult health conditions, including diabetes, obesity, hypertension, thyroid diseases, metabolic disorders, and preventive medicine. He aims to create personalized diagnostic and management plans by evaluating each patient through a holistic lens.

After completing his primary and secondary education, he enrolled at Istanbul University Istanbul Faculty of Medicine (Capa) in 1993 and graduated in 1999 as a Medical Doctor. Following his early experience as a general practitioner, he began his residency in the Department of Internal Medicine at Dicle University Faculty of Medicine, becoming an Internal Medicine Specialist in 2008. Advancing rapidly in his academic career, Dr. Pasa successfully passed the associate professorship examination at Cerrahpasa Faculty of Medicine to earn the title of Associate Professor in 2010, followed by Full Professor at Mardin Artuklu University Faculty of Medicine in 2017.

Grounded in evidence-based medicine and guided by up-to-date global clinical guidelines, Prof. Dr. Semir Pasa delivers care focused on enhancing patient quality of life through personalized evaluations, continuous monitoring, and multidisciplinary collaboration. Bringing over 20 years of clinical and administrative leadership from Turkey, he has been serving patients in Cyprus at Medicheck Clinic in Famagusta (Gazimagusa) since November 2025.

Education and Academic Credentials

• Professor of Internal Medicine

  Mardin Artuklu University Faculty of Medicine, 2017

• Associate Professor of Internal Medicine

  Istanbul University Cerrahpasa Faculty of Medicine, 2010

• Internal Medicine Residency / Specialization

  Dicle University Faculty of Medicine, 2002 – 2008

• Doctor of Medicine (MD)

  Istanbul University Istanbul Faculty of Medicine (Capa), 1993 – 1999

Professional Work Experience

• Specialist Internal Medicine Physician (Professor)

  Medicheck Clinic, Famagusta, Cyprus (November 2025 – Present)

• Specialist Internal Medicine Physician (Professor)

  Can State Hospital, Canakkale, Turkey (February 2025 – November 2025)

• Specialist Internal Medicine Physician (Professor)

  Medical Park Hospital, Canakkale, Turkey (September 2021 – February 2025)

• Full-Time Academic Faculty Member / Professor

  Mardin Artuklu University, Mardin, Turkey (September 2017 – September 2021)

• Specialist Internal Medicine Physician / Medical Director (Associate Professor)

  Private Baglar Hospital, Diyarbakir, Turkey (October 2012 – September 2021)

• Specialist Internal Medicine Physician / Academic Faculty Member (Associate Professor)

  Elazig Damla Hospital, Elazig, Turkey (March 2011 – October 2012)

• Specialist Internal Medicine Physician / Academic Faculty Member (Associate Professor)

  Adiyaman University Faculty of Medicine, Adiyaman, Turkey (August 2010 – March 2011)

• Specialist Internal Medicine Physician (Associate Professor)

  Diyarbakir Training and Research Hospital, Diyarbakir, Turkey (September 2009 – August 2010)

• Compulsory Service Specialist Physician

  Ergani State Hospital, Diyarbakir, Turkey (March 2008 – September 2009)

• Research Assistant / Resident Physician

  Dicle University Faculty of Medicine, Diyarbakir, Turkey (July 2002 – March 2008)

Areas of Expertise and Clinical Interests

Prof. Dr. Semir Pasa specializes in the following primary clinical domain areas:

• General Internal Medicine Evaluation and Physical Examinations

• Diabetes Mellitus Diagnosis, Treatment, and Routine Management

• Pre-diabetes and Insulin Resistance Management

• Metabolic Status Analysis and Individualized Obesity Treatment

• Hypertension and Associated Chronic Disease Monitoring

• Treatment of Hyperlipidemia and Cholesterol Disorders

• Thyroid Disorders (Hypothyroidism, Hyperthyroidism, Thyroid Nodule Monitoring)

• Gastrointestinal and Liver Diseases

• Chronic Kidney Disease Management

• Anemia, Vitamin, and Mineral Deficiency Treatments

• Preventive Medicine and Customized Health Screenings (Check-Up Programs)

Obesity and Metabolic Diseases

Recognizing that excess weight and obesity are major risk factors for numerous chronic conditions rather than merely aesthetic concerns, personalized treatment plans are developed by evaluating the patient’s metabolic status, comorbidities, and lifestyle habits together.

Diabetes and Insulin Resistance

Applying evidence-based medical therapies within chronic disease management to diagnose diabetes, design targeted treatment plans, reduce complication risks, and reverse insulin resistance.

Preventive Medicine and Health Screenings

Promoting early detection of illnesses through structured health screenings tailored to age, gender, and individual risk profiles. Comprehensive routine check-ups and customized health packages are strongly recommended.

Services Offered at MediHeart Medical Center

Prof. Dr. Semir Pasa actively accepts patients at MediHeart Medical Center for the following services:

• Comprehensive Internal Medicine Examination

• Diabetes Management and Follow-Up

• Hypertension Monitoring

• Clinical Obesity Assessment

• Thyroid Disease Management

• Cholesterol and Lipid Control

• Metabolic Syndrome and Disease Management

• Personalized Check-Up Packages

• Chronic Disease Monitoring and Control

• General Adult Health Evaluation

Publications and Academic Contributions

Books and Book Chapters

• B1. Interdisciplinary Approach to Geriatrics. Ed. Prof. Dr. Umran Sevil. Approach to Chronic Internal Diseases in Geriatric Patients, pp. 25-95.

• B2. Multidisciplinary Health Approaches in Fighting COVID-19. Eds. Pasa S, Yildiz R. MAU Publications, 2021.

• B3. Cirrhosis (2nd Edition). Yilmaz S, Ed. Hematological Changes in Liver Cirrhosis. Ankara: Hipokrat Publishing House, pp. 627-637.

• B4. COVID-19 and Systemic Diseases in Internal Medicine Practice (1st Edition). Keskek SO, Editor. Gastroenterology and COVID-19. Ankara: Turkiye Klinikleri, 2022, pp. 30-42.

International Refereed Journal Articles (SCI / SCI-E / PubMed)

• C1. Bahceci M, Tuzcu A, Pasa S, Ayyildiz O, Tuzcu S. Polyglandular autoimmune syndrome type III accompanied by common variable immunodeficiency. Gynecol Endocrinol. 2004;19:47-50.

• C2. Dursun M, Ozekinci T, Ertem M, Saka G, Yilmaz S, Canoruc F, Celenk S, Celik M, Pasa S, Aydin K. Prevalence of Hepatitis C in adults in the southeastern region of Anatolia. Hepatology Research. 2004;29:75-80.

• C3. Altintas A, Ozel A, Okur N, Okur N, Cil T, Pasa S, Ayyildiz O. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis. 2007;24:163-168.

   

• C4. Altintas A, Pasa S, Akdeniz N, Cil T, Yurt M, Ayyildiz O, Batun S, Isi H. Factor V Leiden and G20210A prothrombin mutations in patients with recurrent pregnancy loss: data from the southeast of Turkey. Ann Hematol. 2007;86:727-731.

• C5. Cil T, Kaplan MA, Altintas A, Pasa S, Isikdogan A. Cytosine-arabinoside induced bradicardia in patients with non-Hodgkin lymphoma: A case report. Leukemia & Lymphoma. 2007;48(6):1247-1249.

• C6. Cil T, Altintas A, Tuzun Y, Pasa S, Isikdogan A. Hepatitis B virus reactivation induced by Yttrium-90-ibritumomab-tiuxetan. Leukemia & Lymphoma. 2007;48(9):1866-1868.

• C7. Altintas A, Karahan Z, Pasa S, Cil T, Boyraz T, Iltumur K, Ayyildiz O. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. Leukemia & Lymphoma. 2007;48(10):1981-1987.

• C8. Yilmaz S, Bayan K, Dursun M, Canoruc F, Pasa S, Saka G. Long-term conventional Interferon Alpha in Combination with Lamivudine for Chronic Hepatitis B: Data from Turkey. Hepato-Gastroenterology. 2007;54:2348-2352.

• C9. Pasa S, Altintas A, Devecioglu B, Cil T, Danis R, Isi H, Bayan K, Tuzun Y, Ecer S, Batun S, Ayyildiz O. Familial Mediterranean fever gene mutations in the Southeastern region of Turkey and their phenotypical features. Amyloid. 2008;15(1):49-53.

   

• C10. Altintas A, Cil T, Pasa S, Kilinc I, Isikdogan A. Successful Surgical Treatment of Renal Cell Carcinoma With Calvarial Metastases. Ann Acad Med Singapore. 2008;37(3):241-242.

• C11. Pasa S, Altintas A, Cil T, Danis R, Subasi M, Ayyildiz O, Muftuoglu E. Successful total hip replacement in a patient with severe haemophilia A with inhibitors using recombinant factor VIIa. Haemophilia. 2008;14:863-865.

• C12. Bahceci M, Pasa S, Akay HO, Tuzcu A, Tumer C, Gokalp D. Serum nitric oxide levels and flow mediated dilatation in patients with Sheehan syndrome and the effect of combination therapy consisting of L-thyroxine, prednisolone, and conjugated estrogen/medroxyprogesterone acetate. Fertility and Sterility. 2008;89(4):995-997.

• C13. Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy. Leukemia & Lymphoma. 2008;49(5):939-947.

   

• C14. Altintas A, Pasa S, Cil T, Bayan K, Gokalp D, Ayyildiz O. Thyroid and celiac disease autoantibodies in patients with adult chronic idiopathic thrombocytopenic purpura. Platelets. 2008;19(4):252-257.

• C15. Pasa S, Sayhan MB, Boyraz T, Altintas A. A case of neuroleptic malignant syndrome accompanied by atypical antipsychotic agent: Risperidone. Neurotoxicology. 2008;29:750-751.

• C16. Altintas A, Pasa S, Cil T, Ayyildiz O. Familial Mediterranean Fever accompanied by ankylosing spondylitis: Case report. Turkiye Klinikleri J Med Sci. 2008;28:399-402.

• C17. Pasa S, Beyaz C, Arikan S, Altintas A, Gokalp D, Cil T, Tuzcu A, Bahceci M. Ectopic lingual thyroid as a rare cause of primary hypothyroidism. The Endocrinologist. 2008;18(4):163-164.

• C18. Cil T, Altintas A, Pasa S, Buyukbayram H, Isikdogan A. Primary spindle cell sarcoma of the breast. Breast Care. 2008;3:197-199.

• C19. Altintas A, Cil T, Pasa S, Danis R, Kilinc I, Ayyildiz O, Muftuoglu E. Clinical significance of elevated antinuclear antibody test in patients with Hodgkin’s and Non-Hodgkin’s lymphoma: a single center experience. Minerva Medica. 2008;99:7-14.

• C20. Cil T, Altintas A, Pasa S, Kilinc I, Isikdogan A. Cranial involvement in a follicular lymphoma patient with systemic complete remission after Yttrium-90-Ibritumomab-Tiuxetan treatment. Turkiye Klinikleri J Med Sci. 2008;28(6):953-955.

• C21. Cil T, Altintas A, Pasa S, Isikdogan A. Atypical skin metastases from early tubular breast carcinoma. Int J Dermatol. 2008;47:1311-1313.

• C22. Altintas A, Pasa S, Cil T, Kaplan MA, Ayyildiz O. Retinoic acid syndrome subsequent to the first dose of all trans retinoic acid. J Emerg Med. 2008;35(4):456-457.

• C23. Danis R, Ozmen S, Akin D, Ozekinci S, Altintas A, Cil T, Pasa S, Kilinc I. Thrombosis of temporal artery and renal vein in Kimura disease related nephrotic syndrome. J Thromb Thrombolysis. 2009;27(1):115-118.

• C24. Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O, Muftuoglu E. A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab. J Thromb Thrombolysis. 2009;27(2):220-222.

• C25. Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocytopenic purpura. J Thromb Thrombolysis. 2009;27(3):329-333.

• C26. Pasa S, Altintas A, Cil T, Ustun C, Bayan K, Danis R, Urakci Z, Tuzun Y, Ayyildiz O. Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis?. Int J Infect Dis. 2009;13(1):19-22.

• C27. Cil T, Altintas A, Isikdogan A, Pasa S, Bayan K, Batun S, Buyukbayram H. Screening for celiac disease in Hodgkin and non-Hodgkin lymphoma patients. Turk J Gastroenterol. 2009;20(2):87-92.

• C28. Gokalp D, Tuzcu A, Bahceci M, Arikan S, Bahceci S, Pasa S. Sheehan’s syndrome as a rare cause of anaemia secondary to hypopituitarism. Ann Hematol. 2009;88(5):405-410.

• C29. Pasa S, Bayan K, Kucukoner M, Tuzun Y, Altintas A, Cil T, Danis R, Ayyildiz O. The effects of nonsteroidal anti-inflammatory drugs on platelet function and severity of upper gastrointestinal haemorrhage. J Thromb Thrombolysis. 2009. doi:10.1007/s11239-008-0263-5.

• C30. Pasa S, Altintas A, Cil T, Ayyildiz O. Fetal loss in a patient with acute myeloblastic leukemia associated with Flag-ida regime. UHOD. 2009;19(2):110-112.

• C31. Cil T, Altintas A, Pasa S, Urakci Z, Isikdogan A. Breast carcinoma metastasis to the tail of pancreas. J Breast Health. 2009;5(4):228-230.

• C32. Pasa S, Altintas A, Bayan K, Tuzun Y, Cil T, Ayyildiz O. A case of polycythemia vera accompanied by neurofibromatosis type 1. UHOD. 2010;20(1):45-47.

• C33. Pasa S, Altintas A, Tumer C, Demircin M, Cil T, Bayan K, Danis R, Tuzun Y, Atayan Y, Ayyildiz O, Bahceci M. Prothrombin time, activated thromboplastin time, fibrinogen and D-dimer levels and von-Willebrand activity of patients with Sheehan’s syndrome and the effect of hormone replacement therapy on these factors. UHOD. 2010;20(4):212-219.

• C34. Demir B, Pasa S, Demir S, Tumer C, Atay AE, Gul T, Atamer Y. Hirsutism score and the severity of hyperandrogenism associated with polycystic ovary syndrome in the south-eastern region of Turkey. J Int Med Res. 2011;39(4):1-7.

• C35. Demir B, Pasa S, Buyukkaya R, Demir S, Atay AE, Atamer Y, Gul T. Morphologic and functional vascular alterations in patients with polycystic ovary syndrome. Clin Exp Obst Gyneacol. 2011;38(4):401-404.

• C36. Atay AE, Ozupekce S, Akbas H, Acar M, Pasa S, Oruc M. Tuberous sclerosis presented with polycystic kidney disease and acute renal failure. Arch Iranian Med. 2012;15(6):384-386.

• C37. Demir B, Demir S, Pasa S, Guven S, Atamer Y, Kocyigit Y. The role of homocysteine, asymmetric dimethyl arginine and nitric oxide in pre-eclampsia. J Obst Gyneacol. 2012;32:525-528.

• C38. Atay AE, Seven G, Yalcin K, Pasa S, Degertekin H. Evaluation of hepatitis B viremia levels in patients with HBeAg-negative chronic hepatitis B virus infection. J Int Med Res. 2012;40(5):1891-1896.

• C39. Atay AE, Simsek H, Demir B, Sakar MN, Kaya M, Pasa S, Demir S, Sit D. Noninvasive assessment of subclinical atherosclerosis in normotensive gravidae with gestational diabetes. Herz. 2013. PMID: 23861134.

• C40. Oruc M, Atay AE, Karabulut P, Pasa S, Elbey A, Ekin N, Yildirim S. An unusual case of cavernous hemangioma of the rib in a young man with lung tuberculosis: a brief review and case report. Intern Med. 2013;52(11):1263-1265.

• C41. Balyen L, Deniz Balyen LS, Pasa S. A case of orbital granulocytic sarcoma (chloroma) well responded to treatment. Adv Ophthalmol Vis Syst. 2016;5(1):0039.

• C42. Balyen L, Deniz Balyen LS, Pasa S. Clinical characteristics of Crouzon syndrome. Oman J Ophthalmol. 2017;10:120-122.

• C43. Demir B, Demir SS, Ozkan Karacaer K, Pasa S, Silan F. Evaluation of inflammatory markers of hemogram parameters in primary ovarian insufficiency. Turk J Obstet Gynecol. 2019. doi:10.4274/tjod.galenos.2019.

International Scientific Conference Presentations

• E1. Bahceci M, Pasa S, Akay HO, Tuzcu A, Arikan S, Gokalp D. Effect of hormone replacement therapy apart from growth hormone in patients with Sheehan syndrome. 9th European Congress of Endocrinology, Budapest, Vol.14, P613, BioScientifica, Budapest, 2007.

Articles Published in National Refereed Journals (Turkish)

• F1. Altintas A, Pasa S, Aggul C, Tural B, Ayyildiz O. Retinoic acid syndrome developing after the first dose of all-trans retinoic acid: A case report. UHOD. 2006;16(3):145–148.

• F2. Pasa S, Altintas A, Gokalp D. Sheehan Syndrome: Review. Endokrinolojide Diyalog. 2008;3:143–148.

• F3. Altintas A, Pasa S, Kucukzeybek Y, Demir C, Ayyildiz O. Results of Flag-Ida chemotherapy in recurrent and refractory acute leukemias. Tepecik Egitim Hastanesi Dergisi. 2009;19(3):115–126.

• F4. Demir C, Altintas A, Pasa S, Kaplan MA, Kucukzeybek Y, Ayyildiz O. Assessment of patients with thrombotic thrombocytopenic purpura. East J Med. 2010;15:15–20.

• F5. Atay AE, Akbas H, Sakar N, Pasa S, Ari S, Ekin N. Clinical manifestations of tuberous sclerosis complex. East J Med. 2013;18:52–57.